CARVIVIB 3.125 CARVEDILOL 3.125mg. IP

Carvivib 3.125 tablets with carvedilol 3.125 mg for hypertension, chronic heart failure and to reduce death after a heart attack (LVEF 40% or less). Main uses: management of essential hypertension; treatment of mild to severe chronic heart failure of ischemic or cardiomyopathic origin, usually along with diuretics, ACE inhibitors and digitalis; reduces the risk of hospitalisation in chronic heart failure; reduces cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of 40% or less; can be used alone or with other antihypertensive agents, especially thiazide-type diuretics.

Common side effects of Carvivib 3.125 Tablet include dizziness; fatigue and weakness; low blood pressure (hypotension); diarrhoea; high blood sugar (hyperglycaemia); slow heart rate (bradycardia). Get medical help at once if you notice worsening heart failure and fluid retention; severe slowing of the heart rate; bronchospasm or breathing difficulty.

Each Carvivib 3.125 tablet contains Carvedilol 3.125 mg. The right dose and how long to take it depend on the condition, age and other medicines, so use Carvivib 3.125 Tablet only as your doctor advises.

The MRP of Carvivib 3.125 Tablet is ₹43 for a pack of 10x10 (Blister). For chemists and distributors, the PTR is ₹32.76 and the PTS is ₹29.49.

Each Carvivib 3.125 tablet contains Carvedilol 3.125 mg. It comes in a pack of 10x10 (Blister).

Carvedilol in these tablets works on two types of receptors in the body. By blocking beta-adrenergic receptors it reduces the effect of stress hormones on the heart, so the heart beats with less effort and at a slower rate. At the same time, its alpha-1 blocking action helps relax and widen blood vessels. Together these actions lower the workload on the heart and help bring down raised blood pressure.

Must not be used in bronchial asthma or related bronchospastic conditions. Must not be used in second- or third-degree AV block. Must not be used in sick sinus syndrome, or in severe bradycardia unless a permanent pacemaker is in place. Must not be used in cardiogenic shock, in decompensated heart failure requiring intravenous inotropic therapy, or in severe hepatic impairment. Must not be used if there has been a serious hypersensitivity reaction (e.g. Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or to other medicines containing carvedilol.

Carvivib 3.125 Tablet is a brand of Vibcare Pharma, sold through its Cure division. It is available for PCD pharma franchise and distribution in India; use the Send Enquiry or WhatsApp button on this page to ask about availability and terms.